Insomnia - US Drug Market: Rising Cases of Insomnia to be Biggest Driver

Published Date : Nov 14, 2016

Albany, NY, Nov 14, 2016: Insomnia is one of the common disorders affected to 35% of the worldwide population. Insomnia is primarily classified into primary and secondary subtypes. The number of people suffering from a sleep disorder, insomnia, is increasing in the United States. In the recent past, the launch of new products and drugs to treat insomnia has been benefiting the U.S. insomnia drugs market. The U.S. insomnia market is classified widely, which enables the market to be competitive for the companies. Although the introduction of new treatments, the primary treatment of insomnia is centered on low-dose sedating antidepressants and nonbenzodiazepines. 

The report, titled “Insomnia - US Drug Forecast And Market Analysis To 2023,” states that the introduction of new treatments and drugs for insomnia is expected to propel the U.S. market for insomnia drugs. The top-selling drug of 2014, Sunovion/Dainippon Sumitomo Lunesta, is losing its individuality. This is expected to hamper the growth of the insomnia drug market in the U.S. However, the report’s authors predict that the launch of new products by a novel drug class will offer growth opportunities for the leading players operating in the U.S. insomnia market. With this, leading players will be able to meet some unmet needs, predict the analysts.

The report highlights key companies operating in the insomnia market and also briefs authors about all top-selling products. As per the findings of the report, Belsomra is likely to be the most selling product and by 2023, in the United States, it is likely to generate a sale of US$358.9 mn. Belsomra has dominated the insomnia drugs segment owing to its capacity to address the unmet needs of the market. The insomnia drugs market in the United States is expected to face immense competition from the generic brands, which is likely to be the biggest challenge for the leading players.   

For Sample Copy, click here:

Nonbenzodiazepines, Benzodiazepines, Melatonin Receptor Agonists, Low-Dose Sedating Antidepressants, and Orexin Receptor Antagonists are some of the major products listed in the report. The sale of these branded drugs and treatments is expected to increase, which is likely to benefit the global market in many ways. Key manufacturers are also aiming to participate in partnerships with some of the new entrants, which is anticipated to make the U.S. market for insomnia drugs highly competitive. The large untapped market in the United States is likely to create new growth opportunities for the leading players as well as the new entrants. The growing medical and healthcare infrastructure has helped key companies to manufacture new drugs for treating insomnia. The rising government support and funding has also affected the U.S. market for insomnia drugs in the recent years.

To order report Call Toll Free: 866-997-4948 or send an email on